...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Randomized Phase 2 Study of Radiotherapy Alone versus Radiotherapy with Paclitaxel in Non-Small Cell Lung Cancer
【24h】

Randomized Phase 2 Study of Radiotherapy Alone versus Radiotherapy with Paclitaxel in Non-Small Cell Lung Cancer

机译：非小细胞肺癌单独放疗与紫杉醇放疗的随机2期研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This randomized phase 2 study aimed to assess and compare the toxicity and response rates in patients with unresectable non-small cell lung cancer treated with radiotherapy (1.8-2 Gray [Gy] daily, five fractions a week, total 63 Gy) or radiotherapy + paclitaxel administered weekly (1.8 Gy daily, five fractions a week, total 59.4 Gy). Twelve patients in the latter arm received 30 mg/m2 paclitaxel (median six cycles) over a 3-h infusion once weekly. After assessing toxicity, the remaining nine patients received 60 mg/m2 paclitaxel weekly (median six cycles). Response was evaluated radio-logically 1 month after treatment. Grade 3 toxicity was 20% and 38% in the radiotherapy and chemoradiotherapy groups, respectively. Overall survival rates in complete and objective (complete plus partial) responders and progression-free survival rate of the objective responders were significantly better in the chemoradiotherapy arm. We believe that using paclitaxel in concurrent chemoradiotherapy regimens may be effective in patients with unresectable, locoregionally advanced non-small cell lung cancer.
机译：这项随机化的2期研究旨在评估和比较接受放疗（每天1.8-2 Gray [Gy]，每周五次，总计63 Gy）或放疗+的不可切除的非小细胞肺癌患者的毒性和缓解率。每周服用紫杉醇（每天1.8 Gy，每周5次，总计59.4 Gy）。后一组的12名患者每周3小时输注30 mg / m2紫杉醇（中位六个周期）。在评估毒性后，其余9名患者每周接受60 mg / m2紫杉醇（中位六个周期）。治疗后1个月通过放射学评估反应。在放疗和放化疗组中，3级毒性分别为20％和38％。在放化疗组中，完全和客观（完全和部分）反应者的总生存率和客观反应者的无进展生存率明显更高。我们认为，在并发放化疗方案中使用紫杉醇对无法切除，局部区域晚期非小细胞肺癌的患者可能有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号